Loading
NASDAQHealthcareMedical - Devices
Latest quote
$16.48
$0.00 · 0.00%
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Previous close
$16.48
$0.00 · 0.00%
After-hours
$16.50
+$0.02 · +0.12%
Sep 4, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Day range
Current $16.48
52-week range
Current $16.48
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
72
Undervalued
Sentiment
49
Mixed
Risk
37
Moderate Risk
Momentum
65
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Day range
Current $16.48
52-week range
Current $16.48
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 85.23M USD | 37.21M USD | 2.07M USD | 2.72M USD | 3.56M USD |
| Cost of goods sold | 11.8M USD | 6.19M USD | 635K USD | 686K USD | 671K USD |
| Gross profit | 73.43M USD | 31.02M USD | 1.43M USD | 2.03M USD | 2.88M USD |
| Research and development | 29.25M USD | 13.87M USD | 17.5M USD | 18.58M USD | 13.78M USD |
| Selling, general, and administrative | 43.53M USD | 29.55M USD | 22.11M USD | 17.3M USD | 13.64M USD |
| Operating expenses | 72.77M USD | 43.43M USD | 39.61M USD | 35.89M USD | 27.42M USD |
| Interest income | 2.92M USD | 125K USD | — | — | — |
| Interest expense | — | — | 1.44M USD | 2.69M USD | 1.19M USD |
| Depreciation and amortization | 349K USD | 229K USD | 399K USD | 132K USD | 146K USD |
| Operating income | 660K USD | −12.41M USD | −38.18M USD | −33.85M USD | −24.53M USD |
| Net income | 2.7M USD | −26.39M USD | −47.68M USD | −36.51M USD | −25.65M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$24.50
48.67% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Dec 24, 2019 | 1:700 | — | — |
Stock split | Oct 22, 2019 | 1:100 | — | — |
Stock split | May 2, 2018 | 1:500 | — | — |
Stock split | Nov 6, 2017 | 1:350 | — | — |
Stock split | Jul 21, 2016 | 1:16 | — | — |
Stock split | Apr 9, 2014 | 1:16 | — | — |
Effective Dec 24, 2019
1:700
Effective Oct 22, 2019
1:100
Effective May 2, 2018
1:500
Effective Nov 6, 2017
1:350
Effective Jul 21, 2016
1:16
Effective Apr 9, 2014
1:16
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM12.22M0.02%79.88B USD0.19%$296.01+0.28%
Vanguard Morningstar Total Stock Market ETFVTI10.87M0.00%2.3T USD0.03%$379.73-0.32%
iShares Russell 2000 Value ETFIWN3.73M0.03%14.47B USD0.24%$224.62+0.40%
Vanguard Extended Market ETFVXF3.72M0.00%93.7B USD0.05%$242.66+0.14%
Simplify Propel Opportunities ETFSURI3.72M4.28%88.51M USD2.82%$20.49+0.94%
Vanguard Russell 2000 ETFVTWO1.97M0.01%17.4B USD0.06%$119.62+0.25%
iShares Micro-Cap ETFIWC1.59M0.11%1.47B USD0.60%$196.25+0.69%
U.S. Micro Cap Portfolio ETFDFMC1.35M0.02%7.81B USD0.43%$60.36+0.60%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Value ETFIWNVanguard Extended Market ETFVXFSimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
